The US Food and Drug Administration (FDA) has ordered new safety warnings for popular diabetes and weight-loss medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, over a potential increased risk of a rare eye condition that can cause permanent vision loss. In a drug safety communication issued on November 9, 2026, the FDA said manufacturers of all GLP-1 receptor agonist medicines must add information about non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their product labels. NAION occurs when blood flow to the optic nerve is reduced. The condition can cause sudden, painless vision loss in one eye, sometimes resulting in permanent damage. The FDA said cases have been reported among users of all currently marketed GLP-1 medicines. The agency began investigating the potential connection after a 2024 medical study reported an association between semaglutide use and NAION. Its subsequent assessment included clinical trial data, animal research, post-marketing reports and observational studies. An FDA analysis of 126 clinical trials found 6.4 NAION cases per 100,000 person-years among GLP-1 users, compared with 3.8 cases among participants receiving comparator treatments. The FDA advised patients to contact healthcare professionals immediately if they experience sudden vision changes, blind spots or other visual disturbances. Patients who develop NAION should discuss their treatment with their doctors. The warning highlights a rare but serious potential safety concern as GLP-1 medicines continue to be used for diabetes and obesity treatment.

AdvertisementThe Puranic